Artivion Inc
$ 37.72
2.67%
17 Apr - close price
- Market Cap 1,781,743,000 USD
- Current Price $ 37.72
- High / Low $ 38.52 / 37.10
- Stock P/E 174.95
- Book Value 9.37
- EPS 0.21
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.03 %
- 52 Week High 48.25
- 52 Week Low 22.22
About
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
Analyst Target Price
$51.57
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-06 | 2025-08-07 | 2025-05-05 | 2025-02-13 | 2024-11-07 | 2024-08-08 | 2024-05-06 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0.17 | 0.16 | 0.03 | -0.012 | -0.3936 | -0.05 | -0.05 | 0.06 | -0.1 | -0.24 | -0.07 | -0.33 |
| Estimated EPS | 0.0583 | 0.03 | -0.0033 | 0.045 | 0.0375 | -0.06 | -0.02 | -0.09 | -0.1 | -0.06 | -0.08 | -0.14 |
| Surprise | 0.1117 | 0.13 | 0.0333 | -0.057 | -0.4311 | 0.01 | -0.03 | 0.15 | 0 | -0.18 | 0.01 | -0.19 |
| Surprise Percentage | 191.5952% | 433.3333% | 1009.0909% | -126.6667% | -1149.6% | 16.6667% | -150% | 166.6667% | 0% | -300% | 12.5% | -135.7143% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.06 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.0275 | $0.0275 | $0.0275 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AORT
2026-04-14 13:40:12
Artivion (AORT) has gained attention following FDA approval of its NEXUS Aortic Arch System, leading to a rise in its stock price and activating an option to acquire developer Endospan. While one valuation model suggests the stock is 25% undervalued at $51.43, another perspective, based on P/S ratios, indicates it might be richly priced compared to industry peers. The article encourages investors to weigh both the potential upside from growth catalysts and the premium valuation before making investment decisions.
2026-04-11 12:39:17
Tudor Investment Corp ET AL reduced its stake in Artivion, Inc. (NYSE:AORT) by 36.7% in the third quarter, selling 39,388 shares. This sale left the firm with 68,021 shares, valued at $2.88 million, representing about 0.14% of the company. Despite insider selling totaling 133,043 shares, Artivion reported stronger-than-expected Q3 earnings with $0.17 EPS and a 19.2% revenue increase, leading analysts to maintain a "Moderate Buy" rating with a $51 average price target.
2026-04-10 22:39:07
Artivion Inc (AORT) saw its shares surge 3.1% to $37.63 on April 10, 2026, despite being considered 46.0% overvalued by GuruFocus' GF Value estimate of $25.77. The company boasts a strong GF Score of 85/100, driven by excellent growth and momentum, while financial strength, profitability, and valuation scores are moderate. Insider activity shows significant selling with no buying over the last three months, suggesting a lack of insider confidence.
2026-04-09 00:10:14
Artivion, Inc. (NYSE:AORT) announced that the U.S. Food and Drug Administration has approved the premarket approval application for the NEXUS Aortic Arch System, developed by Endospan Ltd. This system offers a minimally invasive treatment for aortic arch disease, including chronic aortic dissections, providing an alternative to open-chest surgery. Artivion is now evaluating its option to acquire Endospan, having secured financing for a potential acquisition.
2026-04-08 22:39:24
Artivion (AORT) shares recently jumped 5.3% due to investor optimism following FDA premarket approval for the NEXUS Aortic Arch System, developed by its partner Endospan Ltd., which gives Artivion an option to acquire Endospan. While the company anticipates significant revenue growth, its earnings per share for the upcoming quarter are expected to remain flat, and the Zacks Rank indicates a "Hold" position, suggesting that sustained upside might depend on future earnings estimate revisions.
2026-04-08 20:39:44
Artivion (NYSE:AIVN) announced it received FDA approval for its NEXUS aortic arch cannulation device, expanding its aortic surgery product portfolio. This approval comes as the company continues to evaluate a potential acquisition of Endospan, which would further bolster its position in the endovascular market. The company also reported strong financial results for Q4 2023, exceeding expectations.
